Overzicht activiteiten werkgroep medicamenteuze therapie

Slides:



Advertisements
Similar presentations
FOLFOXIRI plus bevacizumab (bev) vs FOLFIRI plus bev
Advertisements

Oncologic Drugs Advisory Committee
Gynecologic Oncology Group Gynecologic Oncology Group Uterine Corpus Trials: GCIG David Scott Miller, M.D., F.A.C.O.G., F.A.C.S. Director and Dallas Foundation.
Endometrial Cancer May 2007 Dr Anna Winship Guy’s & St. Thomas’ NHS Trust Click Here For First Question Oncology Registrars’ Forum “Best of Five”
Chemotherapy Prolongs Survival for Isolated Local or Regional Recurrence of Breast Cancer: The CALOR Trial (Chemotherapy as Adjuvant for Locally Recurrent.
1 N9841: A Randomized Phase III Equivalence Trial of Irinotecan (CPT-11) versus FOLFOX4 in Patients with Advanced Colorectal Carcinoma Previously Treated.
Endometrial Cancer Surgical Staging (Role of Lymphadenectomy) Karl Podratz MD PhD FACS.
Ovarian Cancer Gloria S. Huang, M.D. Assistant Professor Department of Obstetrics & Gynecology and Women ’ s Health Division of Gynecologic Oncology Albert.
A significant increase in the incidence of endometrial cancer. This increased incidence of endometrial cancer has been widely interpreted to be a result.
Memorial Sloan-Kettering Cancer Center
District 1 ACOG Medical Student Teaching Module 2009
ICTW, Cordoba, Argentina Clinical Research Design & Methodology: Phase III Trials Ian Tannock, MD, PhD, DSc Princess Margaret Cancer Centre & University.
Endometrial Cancer ASSOCIATE PROFESSOR Iolanda Blidaru MD, PhD.
Gynaecologische Tumoren: Internationale richtlijnen en Nieuwe perspectieven in diagnostiek en behandeling SYMPOSIUM ONCOLOGIE – 7 JUNI 2008 Philippe Van.
Clinical Research Design & Methodology: Phase II and III Trials
Endometrial Carcinoma Fuat Demirkıran, MD Istanbul University, Cerrahpaşa School Of Medicine, OB&GYN Department, Gyn Oncology.
Wildiers H, et al. Lancet Oncol. 2007;8:1101. Breast Cancer in Elderly (>65 Years) Recommendations of the International Society of Geriatric Oncology Surgical.
Adjuvant gemcitabine plus docetaxel for completely resected stage I-IV high grade uterine leiomyosarcoma: results of a phase II trial Martee L. Hensley,
4% of all female cancers 25% of all gynecologic cancers life time risk: 1/70 ¾ advanced stage most lethal Epithelial Ovarian Cancer:
1 Phase II trial of sequential gemcitabine and carboplatin followed by paclitaxel as first-line treatment of advanced urothelial carcinoma Presented by.
Endometrial Carcinoma
Are there benefits from chemotherapy to early endometrial cancer
The Carry-Over Effect of Adjuvant Zoledronic Acid: Comparison of 48- and 62-Month Analyses of ABCSG-12 Suggests the Benefits of Combining Zoledronic Acid.
Update on treatment modalities of uterine sarcomas Amant Frederic MD PhD Gynaecological Oncologist UZ Gasthuisberg Katholieke Universiteit Leuven Belgium.
Istituto Nazionale per la Ricerca sul Cancro Genoa – Italy
THE OUTBACK TRIAL A Phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared.
MAX: International multi-centre randomised phase II/III study of capecitabine (Cap), bevacizumab (Bev) and mitomycin C (MMC) as first-line treatment for.
Endometrial Committee David Scott Miller, M.D., F.A.C.O.G., F.A.C.S. Director and Dallas Foundation Chair in Gynecologic Oncology Professor of Obstetrics.
MEASURING CLINICAL EFFICACY IN PHASE II TRIALS Response: Karnofsky, WHO, RECIST Event rate: progression free/survival Time to event: progression/survival.
Malignant & Pre-malignant Diseases of the Endometrium Jose B Moran MD Assistant Professor III Section of Gynecologic Oncology Department of Obstetrics.
SNDA Letrozole (Femara®) Indication: First-line therapy in post- menopausal women with advanced breast cancer. Prior approval: Second-line therapy.
Adjuvant treatment for endometrial cancer Ameri A Associate Professor of Radiation Oncology Shahid Beheshti University of Medical Sciences Dec Pars.
MITO 25 A randomized phase II trial of Carboplatin-Paclitaxel- Bevacizumab vs Carboplatin-Paclitaxel-Bevacizumab- Rucaparib vs Carboplatin-Paclitaxel-Rucaparib.
Erlotinib plus Gemcitabine Compared with Gemcitabine Alone in Patients with Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute.
MITO 25 A randomized phase II trial of Carboplatin-Paclitaxel-Bevacizumab vs Carboplatin-Paclitaxel-Bevacizumab-Rucaparib vs Carboplatin-Paclitaxel-Rucaparib.
HE-4 TRIAL Prospective phase II trial on the prognostic and predictive value of HE-4 regression during neoadjuvant chemotherapy for advanced ovarian, Fallopian.
PURPOSE PURPOSE METHODSMETHODS CONCLUSIONSCONCLUSIONS Long-term results of daily HDR brachytherapy in the postoperative setting of endometrial carcinoma.
Department of Surgical, Oncological and Oral Sciences U.O.C Medical Oncology Director: Prof A. Russo Ovarian cancer Case Report 1 Dr. Lorena Incorvaia,
Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal- cell carcinoma after radical nephrectomy: phase III,
What’s New in Endometrial Cancer Henry Kitchener April 2009.
RANDOMIZED PHASE II STUDY OF NABPACLITAXEL, IN RECURRENT ADVANCED OR METASTATIC CERVICAL CANCER MITO CER-NAB Enrica Mazzoni, MD Medical Oncology & Breast.
12 th Annual CTOS Meeting 2006 SINGLE AGENT DOXORUBICIN VS DOSE INTENSIVE COMBINATION THERAPY WITH EPIRUBICIN / IFOSFAMIDE IN PREVIOUSLY UNTREATED ADULT.
ELIGIBILITY CRITERIA- Summarised
MITO 25 A randomized phase II trial of Carboplatin-Paclitaxel-Bevacizumab vs Carboplatin-Paclitaxel-Bevacizumab-Rucaparib vs Carboplatin-Paclitaxel-Rucaparib.
Randomized Phase III Study Of Gemcitabine
LION (Phase III Trial): Lymphadenectomy for LN-Negative Advanced Ovarian Cancer Following Complete Resection CCO Independent Conference Highlights* of.
Adjuvant chemotherapy for early stage epithelial ovarian cancer
Gazi ABDULHAY, Sebile GÜLER ÇEKİÇ
Dose dense chemotherapy in the adjuvant treatment of ovarian cancer
Liver surgery for metachronous hepatic metastases with uterine body and uterine cervix origin – a single center experience Nicolae Bacalbasa (1), Irina.
Supplemental Figure 1: FOXM1 mRNA level analysis in 48 ovarian tissues
Alessandra Gennari, MD PhD
Uterine serous carcinoma is more aggressive than high-grade serous ovarian carcinoma: a retrospective study H. Nagano1, Y. Tachibana1, M. Kawakami1, M.
PHASE I/II STUDY OF PEGYLATED LIPOSOMAL DOXORUCIN (PLD) AND GEMCITABINE (GEM) IN RECURRENT PLATIN RESISTANT OVARIAN CANCER (OC). A Study of the VWOG.
Prognostic and Predictive Value of the 21-Gene Recurrence Score Assay in Postmenopausal Women with Node-Positive, Estrogen- Receptor-Positive Breast Cancer.
Amant F – Gynecological Oncology - UZ Gasthuisberg, Leuven
S1207: Phase III randomized, placebo-controlled trial adding 1 year of everolimus to adjuvant endocrine therapy for patients with high-risk, HR+, HER2-
LUCIE Localised Urothelial Carcinoma Immuno-oncology Evaluation Randomised Phase II trial, evaluating safety and efficacy of a combination therapy of.
Uterine cancer Uterine mesenchymal neoplasms
Benefits of switching postmenopausal women with hormone-sensitive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: Combined results.
بررسی اثرتشخیصی تکنسیوم 99 و متیلن بلو در بررسی گرفتاری گره لنفاوی sentinel در بیماران مبتلا به سرطان اندومتر کم خطر استاد راهنما: سرکار خانم دکترفریبا.
Treatment of HR+ Breast Cancer: A Clinical Update
Vitolo U et al. Proc ASH 2011;Abstract 777.
Ganim Khatib, MD Çukurova University Gynecological Oncology
Management of endometrial cancer found on routine hysterectomy for benign disease Prof Dr M Anıl Onan MAY ANTALYA.
LV5FU2-cisplatin followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: Preliminary results of a randomized phase III trial (FFCD.
MITO 26 PHASE II TRIAL ON TRABECTEDIN IN THE TREATMENT OF ADVANCED UTERINE AND OVARIAN CARCINOSARCOMA (CS)
1University Hospital Gasthuisberg, Leuven, Belgium;
MITO 29 Randomized Phase II study on Decitabine plus Carboplatin versus physician’s choice chemotherapy in recurrent, platinum-resistant ovarian cancer.
ENDOMETRIAL CARCINOMA
Presentation transcript:

Overzicht activiteiten werkgroep medicamenteuze therapie Patrick Berteloot

Caelyx-Gemcitabine (ovariumca): afgesloten Tagas (borstca): afgesloten Chirurgisch stadium I-II sereus/ clear cell endometriumca en rol van adjuvant chemo: studie is open voor inclusie S51257-CYP-TAMBRUT: nieuw voostel

Randomized trial UPSC/CC/mixed Surgical staging: HT, BSO, Cytology, Omentectomy, Pelvic lymph node dissection, peritoneal biopsies No further treatment Adjuvant chemotherapy

End-points Primary end-point: disease free survival after three years Secondary end-point: overall survival after three years

Inclusion criteria Patients must meet all of the following inclusion criteria: Histological proven serous or clear cell endometrial cancer (mixed endometrial carcinomas with serous or clear cell component, irrespective of percentage of serous or clear cells are allowed) Adequate staging procedure including hysterectomy, bilateral salpingo-oophorectomy, cytology, adequate pelvic lymphadenectomy, omentectomy, peritoneal biopsies FIGO surgical stage I-IIa Patients must be fit to receive combination chemotherapy and optimal surgical staging (see below) Patients must have adequate bone marrow, renal, hepatic and pulmonary function WHO performance status 0 or 1 > 18 years of age

Exclusion criteria - Endometrial cancer of the following subtype: uterine leiomyosarcoma, endometrial stromal sarcoma, carcinosarcoma, undifferentiated endometrial cancer, endometrioid endometrial cancer (any grade) Endometrial carcinoma with positive pelvic nodes (Stage IIIc) or evidence for transperitoneal spread (Stage IV).

Statistical analysis A randomized Phase III trial is set up to directly compare the two treatment arms. Patients will be randomized to receive either adjuvant chemo or no chemotherapy. The design will test for superiority of the chemotherapy arm over the no chemo arm. Design: Randomized Phase III. Primary endpoint: PFS rate at 3 years. Statistical test: Fisher exact test (2-sided) Parameters: alpha error = 0.05 beta error = 0.20 Expected rate in the control arm (no chemo) = 69% PFS at 3 yrs Expected rate in the experimental arm (chemo) = 95% PFS at 3 yrs Sample size: 2 x 38 patients = 76 patients in total.

Current status Approved by ethical committee in Leuven and 9 Flemish centers (01-2008) Trial is open for inclusion Two patients included

Caelyx-Gemcitabine (ovariumca): afgesloten Tagas (borstca): afgesloten Chirurgisch stadium I-II sereus/ clear cell endometriumca en rol van adjuvant chemo: studie is open voor inclusie S51257-CYP-TAMBRUT: nieuw voostel

Tamoxifen metabolism Endoxifen Gjerde, et al. Ann Oncol 2003; 19:56-61

1. Retrospective study Functional polymorphisms of cytochrome P450 in women without the tamoxifen induced endometrial changes and a reference population. Objective: To study the relation between CYP 450 polymorphisms and endometrial changes under tamoxifen. Study population: 50 postmenopausal women with ER+ breast cancer and no endometrial changes due to tamoxifen Reference populations 50 postmenopausal women with ER+ breast cancer and endometrial changes due to tamoxifen 500 women with breast cancer and 500 women without breast cancer Retrospective, monocentric study

2. Prospective study Response to tamoxifen in metastatic ER+ breast cancer in women with a low and high ‘tamoxifen activity score’ based on CYP 450 polymorphisms and drug interaction. Objective: To study the relation between the efficacy of tamoxifen in terms of progression free survival and the ‘tamoxifen activity score’. Study populations: two groups of postmenopausal women with ER+ metastatic breast cancer (N=140) Low ‘tamoxifen activity score’ High ‘tamoxifen activity score’ Prospective, multicentric study

3. Prospective study Tamoxifen related endometrial changes in ER+ breast cancer in women with a low and high ‘tamoxifen activity score’ based on CYP 450 polymorphisms and drug interaction. Objective: To study the relation between endometrial changes under tamoxifen and the ‘tamoxifen activity score’. Study population: two groups of postmenopausal women with ER+ breast cancer who will start on tamoxifen (N=500) Low ‘tamoxifen activity score’ High ‘tamoxifen activity score’ Prospective, multicentric study